Teladoc Health (TDOC) to Release Earnings on Wednesday

Teladoc Health (NYSE:TDOC) is projected to post its Q1 2026 results after the market closes on Wednesday, April 29th. Analysts expect Teladoc Health to post earnings of ($0.3412) per share and revenue of $613.8170 million for the quarter. Teladoc Health has set its Q1 2026 guidance at -0.450–0.350 EPS and its FY 2026 guidance at -1.100–0.700 EPS. Investors can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Wednesday, April 29, 2026 at 5:00 PM ET.

Teladoc Health (NYSE:TDOC) last announced its earnings results on Wednesday, February 25th. The health services provider reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.05. The firm had revenue of $642.27 million for the quarter, compared to analyst estimates of $635.33 million. Teladoc Health had a negative net margin of 7.92% and a negative return on equity of 9.13%. Teladoc Health’s revenue was up .3% compared to the same quarter last year. During the same quarter last year, the business earned ($0.28) earnings per share. On average, analysts expect Teladoc Health to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Teladoc Health Stock Up 0.6%

Shares of TDOC opened at $5.79 on Monday. The firm has a market cap of $1.04 billion, a PE ratio of -5.07 and a beta of 2.07. The company’s fifty day moving average is $5.29 and its two-hundred day moving average is $6.51. Teladoc Health has a fifty-two week low of $4.40 and a fifty-two week high of $9.77. The company has a quick ratio of 2.67, a current ratio of 2.77 and a debt-to-equity ratio of 0.72.

Insiders Place Their Bets

In other news, CEO Charles Divita III sold 27,731 shares of the stock in a transaction on Wednesday, March 11th. The shares were sold at an average price of $5.49, for a total transaction of $152,243.19. Following the transaction, the chief executive officer owned 364,784 shares in the company, valued at $2,002,664.16. This represents a 7.06% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.70% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. IFP Advisors Inc boosted its holdings in Teladoc Health by 412.1% in the 3rd quarter. IFP Advisors Inc now owns 3,989 shares of the health services provider’s stock valued at $31,000 after purchasing an additional 3,210 shares during the period. PNC Financial Services Group Inc. lifted its holdings in Teladoc Health by 177.7% during the 4th quarter. PNC Financial Services Group Inc. now owns 4,391 shares of the health services provider’s stock valued at $31,000 after purchasing an additional 2,810 shares during the last quarter. Van ECK Associates Corp lifted its holdings in Teladoc Health by 101.4% during the 4th quarter. Van ECK Associates Corp now owns 9,150 shares of the health services provider’s stock valued at $64,000 after purchasing an additional 4,607 shares during the last quarter. Johnson Financial Group Inc. lifted its holdings in Teladoc Health by 41,045.8% during the 3rd quarter. Johnson Financial Group Inc. now owns 9,875 shares of the health services provider’s stock valued at $76,000 after purchasing an additional 9,851 shares during the last quarter. Finally, Envestnet Asset Management Inc. bought a new position in Teladoc Health during the 2nd quarter valued at about $89,000. 76.82% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have commented on TDOC shares. Oppenheimer cut their price objective on shares of Teladoc Health from $12.00 to $7.00 and set an “outperform” rating on the stock in a report on Tuesday, March 3rd. Deutsche Bank Aktiengesellschaft raised shares of Teladoc Health from a “hold” rating to a “buy” rating and set a $11.00 target price for the company in a research report on Tuesday, March 10th. Barclays decreased their price target on shares of Teladoc Health from $8.50 to $7.00 and set an “equal weight” rating for the company in a report on Thursday, March 26th. TD Cowen decreased their price target on shares of Teladoc Health from $8.00 to $6.00 and set a “hold” rating for the company in a report on Thursday, February 26th. Finally, Leerink Partners reduced their target price on shares of Teladoc Health from $8.50 to $5.50 and set a “market perform” rating for the company in a research note on Thursday, February 26th. Six analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $7.62.

About Teladoc Health

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.